Cancel
Aera Therapeutics
See Linkedin
Aera Therapeutics Employees
8 people indexed:
-
zzgp.4plw3@26pwvb.308 Sign up to see email
-
David Schenkein
Board Director
-
wvp0.8iq0l@70q2vs.5sy Sign up to see email
-
Issi Rozen
Board Observer
-
John Maraganore
Board Chair
-
Josh Wolfe
Board Director
-
Robert Nelsen
Board Director
-
Vicki Sato
Board Director
Aera Therapeutics Company Information
Aera Therapeutics, headquartered at 300 Technology Square, Cambridge, MA 02139, was launched with $193 million in financing to enable and advance the next generation of transformative genetic medicines. The company utilizes a proprietary protein nanoparticle (PNP) delivery platform based on endogenous human proteins to develop genetic medicines targeting a wide range of therapeutic applications. Additionally, Aera Therapeutics has licensed technology that includes a proprietary therapeutic enzyme platform for gene editing, further enhancing its capabilities in the field of genetic medicine.
Report inaccurate information
Report inaccurate information
